Representative Lisa C. McClain (R-Michigan) recently sold shares of West Pharmaceutical Services, Inc. NYSE: WST. In a filing disclosed on August 13th, the Representative disclosed that they had sold between $1,001 and $15,000 in West Pharmaceutical Services stock on July 22nd. The trade occurred in the Representative's "CHARLES SCHWAB BROKERAGE ACCOUNT 924" account.
Representative Lisa C. McClain also recently made the following trade(s):
- Sold $1,001 - $15,000 in shares of Autoliv NYSE: ALV on 8/4/2025.
- Sold $1,001 - $15,000 in shares of Amazon.com NASDAQ: AMZN on 8/4/2025.
- Sold $1,001 - $15,000 in shares of Applied Materials NASDAQ: AMAT on 8/4/2025.
- Sold $1,001 - $15,000 in shares of Arthur J. Gallagher & Co. NYSE: AJG on 8/4/2025.
- Sold $1,001 - $15,000 in shares of SAP NYSE: SAP on 7/22/2025.
- Purchased $1,001 - $15,000 in shares of XPO NYSE: XPO on 7/22/2025.
- Purchased $1,001 - $15,000 in shares of Lithia Motors NYSE: LAD on 7/22/2025.
- Sold $1,001 - $15,000 in shares of Sanofi NASDAQ: SNY on 7/22/2025.
- Sold $1,001 - $15,000 in shares of Waters NYSE: WAT on 7/22/2025.
- Purchased $1,001 - $15,000 in shares of Group 1 Automotive NYSE: GPI on 7/22/2025.
West Pharmaceutical Services Stock Performance
WST stock traded down $0.04 during trading on Friday, hitting $246.16. 781,012 shares of the company traded hands, compared to its average volume of 841,898. The stock's 50-day simple moving average is $230.05 and its 200 day simple moving average is $227.78. The company has a debt-to-equity ratio of 0.07, a current ratio of 2.78 and a quick ratio of 2.08. The company has a market cap of $17.70 billion, a PE ratio of 36.85, a P/E/G ratio of 4.37 and a beta of 1.05. West Pharmaceutical Services, Inc. has a 1 year low of $187.43 and a 1 year high of $352.33.
West Pharmaceutical Services (NYSE:WST - Get Free Report) last posted its quarterly earnings data on Thursday, July 24th. The medical instruments supplier reported $1.84 EPS for the quarter, beating analysts' consensus estimates of $1.51 by $0.33. West Pharmaceutical Services had a return on equity of 18.43% and a net margin of 16.48%. The business had revenue of $766.50 million during the quarter, compared to analysts' expectations of $725.11 million. During the same period in the previous year, the business earned $1.52 earnings per share. The business's revenue was up 9.2% compared to the same quarter last year. On average, equities analysts expect that West Pharmaceutical Services, Inc. will post 6.62 earnings per share for the current fiscal year.
West Pharmaceutical Services Increases Dividend
The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, November 19th. Stockholders of record on Wednesday, November 12th will be issued a $0.22 dividend. This is a boost from West Pharmaceutical Services's previous quarterly dividend of $0.21. This represents a $0.88 dividend on an annualized basis and a dividend yield of 0.4%. The ex-dividend date of this dividend is Wednesday, November 12th. West Pharmaceutical Services's dividend payout ratio is currently 12.57%.
Institutional Trading of West Pharmaceutical Services
A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Boston Trust Walden Corp grew its stake in shares of West Pharmaceutical Services by 4.7% in the first quarter. Boston Trust Walden Corp now owns 1,110 shares of the medical instruments supplier's stock worth $249,000 after acquiring an additional 50 shares during the period. SYM FINANCIAL Corp increased its position in West Pharmaceutical Services by 5.1% in the second quarter. SYM FINANCIAL Corp now owns 1,027 shares of the medical instruments supplier's stock worth $225,000 after purchasing an additional 50 shares during the last quarter. Benjamin Edwards Inc. increased its position in West Pharmaceutical Services by 1.7% in the second quarter. Benjamin Edwards Inc. now owns 3,021 shares of the medical instruments supplier's stock worth $661,000 after purchasing an additional 50 shares during the last quarter. Parkside Financial Bank & Trust increased its position in West Pharmaceutical Services by 4.0% during the second quarter. Parkside Financial Bank & Trust now owns 1,318 shares of the medical instruments supplier's stock valued at $288,000 after acquiring an additional 51 shares during the last quarter. Finally, MJP Associates Inc. ADV lifted its stake in West Pharmaceutical Services by 2.7% in the second quarter. MJP Associates Inc. ADV now owns 1,970 shares of the medical instruments supplier's stock worth $431,000 after acquiring an additional 52 shares during the period. Institutional investors own 93.90% of the company's stock.
Wall Street Analysts Forecast Growth
Several equities analysts have recently issued reports on the company. Wall Street Zen upgraded West Pharmaceutical Services from a "hold" rating to a "buy" rating in a research note on Saturday, July 26th. Evercore ISI boosted their target price on West Pharmaceutical Services from $275.00 to $350.00 and gave the stock an "outperform" rating in a research report on Friday, July 25th. UBS Group upped their target price on West Pharmaceutical Services from $285.00 to $320.00 and gave the company a "buy" rating in a research note on Friday, July 25th. Citigroup restated a "buy" rating on shares of West Pharmaceutical Services in a research note on Thursday, May 22nd. Finally, Barclays began coverage on West Pharmaceutical Services in a report on Tuesday, June 24th. They set an "equal weight" rating and a $245.00 target price on the stock. Two research analysts have rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, West Pharmaceutical Services presently has an average rating of "Moderate Buy" and an average price target of $320.71.
Read Our Latest Research Report on WST
About Representative McClain
Lisa McClain (Republican Party) is a member of the U.S. House, representing Michigan's 9th Congressional District. She assumed office on January 3, 2023. Her current term ends on January 3, 2027.
McClain (Republican Party) is running for re-election to the U.S. House to represent Michigan's 9th Congressional District. She declared candidacy for the 2026 election.
Lisa McClain lives in Romeo, Michigan. McClain earned a bachelor's degree in business administration from Northwood University. Her career experience includes founding and working as the president of North End Support Team.
West Pharmaceutical Services Company Profile
(
Get Free Report)
West Pharmaceutical Services, Inc designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products.
Featured Articles
Before you consider West Pharmaceutical Services, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and West Pharmaceutical Services wasn't on the list.
While West Pharmaceutical Services currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
MarketBeat All Access